** Shares of biotech investor Royalty Pharma RPRX.O fall 1.3% to $31.81
** RPRX says it is providing up to $250 mln in funding to Biogen BIIB.O to support the development of litifilimab, a potential treatment for systemic lupus erythematosus $(SLE)$ and cutaneous lupus erythematosus $(CLE.AU)$
** SLE and CLE are two forms of the autoimmune disease lupus that affect multiple organs and the skin, respectively, and is currently in late-stage trial
** RPRX says the funding will be provided over six quarters in exchange for regulatory milestones and royalties on future worldwide sales of litifilimab
** Late-stage trial data are expected between 2026 and 2027
** RPRX fell 9.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。